In line with this, the analysis of the clinical and biochemical parameters at baseline and at 12 months after LRYGB of 30 out of our 75 patients without second liver biopsy also showed a significant improvement of fasting insulin, glycaemia, HOMA-IR, metabolic syndrome, diabetes, and CRP (Table 2). This evidence concerns the gene CRP and metabolic syndrome.